Fri, Aug 1, 2014, 1:47 AM EDT - U.S. Markets open in 7 hrs 43 mins


% | $
Click the to save as a favorite.

Corrections Corporation of America Message Board

Doctor_Of_Value 4 posts  |  Last Activity: Jul 6, 2014 1:29 PM Member since: Feb 19, 1999
SortNewest  |  Oldest  |  Highest Rated Expand all messages
  • Reply to

    doctor of value, are you still here?

    by devilsyankeesfan Jun 13, 2014 11:07 AM
    doctor_of_value doctor_of_value Jul 6, 2014 1:29 PM Flag

    I have not left. I own over 1% of the company and remain very bullish on the technology. I am somewhat disappointed at the slow pace of the CardioPet trial. I realize the Belgian hospital is not a big cardiac center and suitable candidates are slow to present themselves. Thijs Spoor has stated several times that this trial is very close to completion meaning to me we have one, two, or three more scans to complete. Trial results from CardioPet are crucial to gaining a partner to fund both CardioPet and BFPet Phase III trials. Because of the extra time it has taken to complete the CardioPet Phase II trial, it seems likely the company will need to raise additional funds on its own to conclude the BFPet Phase II trial.

    The BFPet trial should have already begun enrollment but has not. Last week's 8K filing explains that delay. We should hear news in July regarding the first patient being scanned and as I understand it, this trial should move rapidly because there is no shortage of qualified candidates. All in all, I would say we are about three months behind plan regarding the trials, but we are light years ahead in building a management team, a scientific advisory board and Board of Directors. This part of the equation is really quite remarkable. Still a risky investment, but the probability of success is increasing rapidly.

    Sentiment: Strong Buy

  • doctor_of_value doctor_of_value Jun 13, 2014 8:09 AM Flag

    WST, it doesn't make a lot of sense to me either. Calhoun is looking for a new job to support his life style. Perhaps something was already far enough down the road to just let Calhoun handle it so everyone else could focus on Barda. Just to be clear, I have no opinion on the rumor and don't really believe it. I only mentioned it because Saad correctly would not comment on the rumor. Wish I could recall the sentence but I can't.

  • doctor_of_value doctor_of_value Jun 13, 2014 8:03 AM Flag

    No offense taken. Saad never tells me anything in confidence. That would violate the SEC rules and he is very careful about that. I probably should have not mentioned a rumor that I don't really believe. As far as my last sentence, permit me to clarify. I am referring to all of the small clinical trials conducted by doctors around the world where the Celution system has been the source of the cells. Cytori does not own the data and in many cases is not made privvy to the trial results. Many of us have expressed frustration and some have accused Cytori of withholding clinical data from the stockholders. These trials are generating data, which is progress. My comment was to express my frustration over the lack of knowledge about these trials. Regenerative medicine has a long way to go before it becomes recognized as "the next big thing." Strong US based clinical data is the key. Success with Barda is a statement from the US government that the technology works. Clinical data from Athena is a statement from the medical world that the technology works.

  • doctor_of_value doctor_of_value Jun 12, 2014 7:02 PM Flag

    Good post, hearnelaura! I was in San Diego last night and met Mark Saad after work. He was very clear saying that Barda had reviewed and approved the shareholder letter that was posted on the website. In fact, it was Barda who changed the wording to: "During the initial base period of the contract, three targeted milestones were completed, potentially allowing Barda to expand the contract award beyond the base period funding," Again, that sentence was added by Barda. While the odds a ridiculously low, it is still possible the panel could deviate from the expected decision. If I remember correctly, there were six different government agencies in the room and all were highly interested in the project.

    Because the outcome of the IPR meeting was unknown, David Rickey was legally able to buy stock on the previous Friday. Saad is looking to use the ATM at prices above $3. A number of large institutional money managers consider a Barda contract beyond the initial base period provides enough justification to buy the stock. In the coming quarters, we should see new names as owners.

    I had heard some rumors that Chris Calhoun was in the UK and still working on a deal. When I asked Saad about that, he clammed up tight and moved away from the question. Not sure how to read that. Calhoun does have a track record of completing small deals, but letting the big ones get away. There is good work being done in Spain in the area of ACL healing. We will see.

    My first purchase was June 22, 2010. All of the progress that has been made over the last four years is behind the scenes and unknown to us. It is about time Cytori actually achieves something of significance.

    Sentiment: Strong Buy

32.22-0.61(-1.86%)Jul 31 4:03 PMEDT

Trending Tickers

Trending Tickers features significant U.S. stocks showing the most dramatic increase in user interest in Yahoo Finance in the previous hour over historic norms. The list is limited to those equities which trade at least 100,000 shares on an average day and have a market cap of more than $300 million.